Paclitaxel and spirulina co-loaded polymeric nanoparticles: in-vitro and in-vivo anticancer study

被引:0
作者
Ravikumar, Yamuna [1 ]
Catherine, Dorcas Pinky [1 ]
Nair, Keerthi G. S. [1 ]
Sekar, Akshya [1 ]
Velmurugan, Ramaiyan [1 ]
机构
[1] Vels Inst Sci Technol & Adv Studies, Sch Pharmaceut Sci, Chennai 600117, Tamil Nadu, India
关键词
Paclitaxel; Spirulina; Nanoparticle; In-vitro; In-vivo; Gastric cancer; CEPHARANTHINE; DELIVERY; CELLS;
D O I
10.1590/s2175-97902020000118996
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Paclitaxel spirulina nanoparticles were said to have promising anticancer activity against gastric cancer. Nanoparticles of paclitaxel-spirulina were prepared for treating gastric cancer using precipitation technique. The synergistic anticancer efficiency against MKN45 cells retains when the paclitaxel and spirulina were encapsulated into nanoparticles. To increase the site specific delivery, intra-tumoral administration was carried in the in vivo evaluation. There was an increase in overall survival in an MKN45-transplanted mice model and notable improvement in anti-tumour efficacy when paclitaxel-spirulina nanoparticles were delivered through intra-tumoral administration. The further investigation of overall anticancer mechanism of these nanoparticles is made as a major part in this research. Hence, the conjecture of this research is that, the paclitaxel-spirulina encapsulated nanoparticles could be an effective chemotherapeutic formulation for gastric cancer.
引用
收藏
页数:9
相关论文
共 16 条
[1]   Drug Delivery Systems for Intraperitoneal Therapy [J].
Bajaj, Gaurav ;
Yeo, Yoon .
PHARMACEUTICAL RESEARCH, 2010, 27 (05) :735-738
[2]   DOCETAXEL (TAXOTERE(R)) - A REVIEW OF PRECLINICAL AND CLINICAL-EXPERIENCE .1. PRECLINICAL EXPERIENCE [J].
BISSERY, MC ;
NOHYNEK, G ;
SANDERINK, GJ ;
LAVELLE, F .
ANTI-CANCER DRUGS, 1995, 6 (03) :339-355
[3]   ASSEMBLY OF PURIFIED GDP TUBULIN INTO MICROTUBULES INDUCED BY TAXOL AND TAXOTERE - REVERSIBILITY, LIGAND STOICHIOMETRY, AND COMPETITION [J].
DIAZ, JF ;
ANDREU, JM .
BIOCHEMISTRY, 1993, 32 (11) :2747-2755
[4]  
Dorr R T, 1994, Ann Pharmacother, V28, pS11
[5]  
Harada K, 2009, ANTICANCER RES, V29, P1263
[6]  
Idani H, 2000, INT J CANCER, V88, P645, DOI 10.1002/1097-0215(20001115)88:4<645::AID-IJC20>3.0.CO
[7]  
2-4
[8]   Cepharanthine potently enhances the sensitivity of anticancer agents in K562 cells [J].
Ikeda, R ;
Che, XF ;
Yamaguchi, T ;
Ushiyama, M ;
Zhang, CL ;
Okumura, H ;
Takeda, Y ;
Shibayama, Y ;
Nakamura, K ;
Jeung, HC ;
Furukawa, T ;
Sumizawa, T ;
Haraguchi, M ;
Akiyama, S ;
Yamada, K .
CANCER SCIENCE, 2005, 96 (06) :372-376
[9]   Gastric cancer treatment in Japan: 2008 annual report of the JGCA nationwide registry [J].
Isobe, Yoh ;
Nashimoto, Atsushi ;
Akazawa, Kohei ;
Oda, Ichiro ;
Hayashi, Kenichi ;
Miyashiro, Isao ;
Katai, Hitoshi ;
Tsujitani, Shunichi ;
Kodera, Yasuhiro ;
Seto, Yasuyuki ;
Kaminishi, Michio .
GASTRIC CANCER, 2011, 14 (04) :301-316
[10]   Global Cancer Statistics [J].
Jemal, Ahmedin ;
Bray, Freddie ;
Center, Melissa M. ;
Ferlay, Jacques ;
Ward, Elizabeth ;
Forman, David .
CA-A CANCER JOURNAL FOR CLINICIANS, 2011, 61 (02) :69-90